NEXUS-01
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- NCT06465069 ↗
- Recruiting
- Eli Lilly and Company
- Deep
We haven't built an HCP commentary report on NEXUS-01 (LY4052031; LY4052031 plus pembrolizumab in advanced or metastatic urothelial carcinoma or solid tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Questions raised in the commentary
Automated from the 33 newest of 34 indexed sources (Nov 2025 – Sep 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- Whether Nectin-4 remains a viable target after EV exposure
- Whether changing payloads can overcome resistance, including after prior Topo-I ADC exposure
- How Nectin-4 ADCs should be sequenced after EV or another ADC
- How CYP2D6 status should guide dosing and toxicity management
Also discussed: adc development landscape.
Indexed commentary on NEXUS-01 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 31 | |
| YouTube | 2 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Metastatic Solid Tumor; Recurrent Solid Tumor; Advanced Solid Tumor; Urinary Bladder Neoplasm; Triple Negative Breast Cancer; Non-small Cell Lung Cancer; Esophageal Cancer; Pancreatic Cancer; Ovarian Cancer; Cervical Cancer; Head and Neck Squamous Cell Carcinoma; Prostate Cancer; Renal Pelvis Cancer; Bladder Cancer
- Interventions
- LY4052031; Pembrolizumab
- Arms
- LY4052031 (Dose-escalation, Cohort A1) · Experimental
- LY4052031 (Dose-optimization, Cohort A2) · Experimental
- LY4052031 (Dose-expansion, Cohort B1, B2, C1) · Experimental
- LY4052031+ Pembrolizumab (Dose-expansion, Cohort D) · Experimental
- Enrollment
- 460 (estimated)
- Primary outcomes
- Phase 1a: To determine the recommended phase 2 dose (RP2D) optimal dose(s) of LY4052031
- Phase 1b: To assess the antitumor activity of LY4052031 as monotherapy or in combination with pembrolizumab: Overall response rate (ORR)
- Sponsor
- Eli Lilly and Company
- Start
- Jul 1, 2024
- Primary completion
- May 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06465069 · updated Oct 22, 2026